### COMMITTEE ON LEGISLATIVE RESEARCH OVERSIGHT DIVISION

### FISCAL NOTE

L.R. No.: 2277H.01I
Bill No.: HB 1118
Subject: Drugs and Controlled Substances; Health Care
Type: Original
Date: February 21, 2025

# FISCAL SUMMARY

ESTIMATED NET EFFECT ON GENERAL REVENUE FUND				
FUND AFFECTED	FY 2026	FY 2027	FY 2028	
	Will exceed	Will exceed	Will exceed	
General	(\$101,767 to	(\$108,382 to	(\$115,427 to	
	\$1,209,526)	\$1,288,145)	\$1,371,874)	
<b>Total Estimated Net</b>	Will exceed	Will exceed	Will exceed	
Effect on General	(\$101,767 to	(\$108,382 to	(\$115,427 to	
Revenue	\$1,209,526)	\$1,288,145)	\$1,371,874)	

\* The range represents the difference between a participant who would be on treatment for a single month or twelve refills per year. **Oversight** assumes unknown costs to DCI will exceed \$250,000 annually.

ESTIMATED NET EFFECT ON OTHER STATE FUNDS					
FUND AFFECTED	FY 2026	FY 2027	FY 2028		
<b>Total Estimated Net</b>					
Effect on Other State					
Funds	\$0	\$0	\$0		

Numbers within parentheses: () indicate costs or losses.

Bill Summary: This proposal creates provisions relating to abuse-deterrent opioid analgesic drug products.

ESTIMATED NET EFFECT ON FEDERAL FUNDS					
FUND AFFECTED	FY 2026	FY 2027	FY 2028		
Federal	\$0	\$0	\$0		
<b>Total Estimated Net</b>					
Effect on <u>All</u> Federal					
Funds	\$0	\$0	\$0		

\* Income and expenses are estimated at \$411,000 to \$4.9 million annually and net to zero. The range represents the difference between a participant who would be on treatment for a single month or twelve refills per year.

ESTIMATED NET EFFECT ON FULL TIME EQUIVALENT (FTE)					
FUND AFFECTED	FY 2026	FY 2027	FY 2028		
<b>Total Estimated Net</b>					
Effect on FTE	0	0	0		

- $\boxtimes$  Estimated Net Effect (expenditures or reduced revenues) expected to exceed \$250,000 in any of the three fiscal years after implementation of the act or at full implementation of the act.
- □ Estimated Net Effect (savings or increased revenues) expected to exceed \$250,000 in any of the three fiscal years after implementation of the act or at full implementation of the act.

ESTIMATED NET EFFECT ON LOCAL FUNDS						
FUND AFFECTEDFY 2026FY 2027FY 20						
Local Government\$0\$0\$0						

# **FISCAL ANALYSIS**

## ASSUMPTION

#### § 208.176 and § 376.1239 - Abuse-deterrent opioid analgesic drug products

Officials from the **Department of Social Services (DSS)** state this legislation amends section 208.176 by adding language that states any prior authorization requirements for opioid analgesic and any service denials made pursuant thereto shall not require use of opioid analgesic drug products without abuse-deterrent properties before authorizing the use of abuse-deterrent opioid analgesic drug products.

It also adds § 376.1239 stating an insurance carrier or health plan shall provide coverage on its formulary, drug list, or other lists of similar constructs for at least one abuse-deterrent opioid analgesic drug product per opioid analgesics active ingredient. This section also adds information on cost-sharing for brand name and generic abuse-deterrent opioid analgesic drug products and addresses prior authorization not being required.

This legislation applies to Chapter 208, which applies MO HealthNet, and to Chapter 376. However, it addresses prescription drugs which are carved out of managed care and covered under the MO Healthnet Fee-For-Service (FFS) Program. In addition, enrollees in the Managed Care Program are not expected to pay cost-sharing amounts. As a result, this legislation would have no fiscal impact on managed care operations or rates.

MHD FFS Pharmacy Program estimates the fiscal impact is \$488,000 to \$5.8 million annually. The range represents the difference between a participant who would be on treatment for a single month or twelve refills per year. A 6.5% inflation rate was applied to FY27 and FY28.

FY26 Total: \$488,000 - \$5,800,000 (GR: \$101,767 - \$1,209,526); (FED: \$386,233 - \$4,590,474)
FY27 Total: \$519,720 - \$6,177,000 (GR: \$108,382 - \$1,288,145); (FED: \$411,338 - \$4,888,855)
FY28 Total: \$553,502 - \$6,578,505 (GR: \$115,427 - \$1,371,874); (FED: \$438,075 - \$5,206,631)

**Oversight** does not have information to the contrary and therefore, Oversight will reflect the estimates as provided by the DSS.

Officials from the **Department of Commerce and Insurance (DCI)** state this proposal requires insurers/health plans to have at least one abuse-deterrent opioid analgesic drug product for each opioid analgesic active ingredient on its formulary and provisions related to the cost-sharing of the drugs. This will have an Unknown impact on DCI: DCI would need to contract with a resource with pharmaceutical knowledge to confirm compliance with these provisions.

L.R. No. 2277H.01I Bill No. HB 1118 Page **4** of **6** February 21, 2025

**Oversight** does not have information to the contrary. Due to a lack of information, Oversight will reflect the estimates as provided by DCI as "Unknown" costs. Oversight assumes the unknown costs could exceed \$250,000 annually.

Officials from the **Department of Public Safety - Missouri Highway Patrol** defer to the Missouri Department of Transportation for the potential fiscal impact of this proposal.

Officials from the **Department of Health and Senior Services**, the **Department of Public Safety - Missouri Veterans Commission**, the **Missouri Consolidated Health Care Plan**, the **Missouri Department of Conservation**, the **Missouri Department of Transportation** and the **Oversight Division** each assume the proposal will have no fiscal impact on their respective organizations. **Oversight** does not have any information to the contrary. Therefore, Oversight will reflect a zero impact in the fiscal note for these agencies.

**Oversight** only reflects the responses received from state agencies and political subdivisions; however, other nursing homes and hospitals were requested to respond to this proposed legislation but did not. A listing of political subdivisions included in the Missouri Legislative Information System (MOLIS) database is available upon request.

FISCAL IMPACT – State Government	FY 2026 (10 Mo.)	FY 2027	FY 2028
GENERAL REVENUE			
GENERAL NEVENUE			
Costs – DSS, MHD (§ 208.176) FFS	(\$101,767 to	(\$108,382 to	(\$115,427 to
Pharmacy Program refill costs p. 3	\$1,209,526)	\$1,288,145)	\$1,371,874)
<u>Costs</u> - DCI (§ 376.1239) Insurance coverage of abuse-deterrent opioid	(Linka over)	(Linknown)	(Uniter over)
analgesic drug products p. 3-4	(Unknown)	(Unknown)	(Unknown)
ESTIMATED NET EFFECT ON GENERAL REVENUE	Will exceed (\$101,767 to <u>\$1,209,526)</u>	Will exceed (\$108,382 to <u>\$1,288,145)</u>	Will exceed (\$115,427 to <u>\$1,371,874)</u>
	(\$101,767 to	(\$108,382 to	(\$115,427 to
	(\$101,767 to	(\$108,382 to	(\$115,427 to
	(\$101,767 to	(\$108,382 to	(\$115,427 to

FISCAL IMPACT – State Government	FY 2026	FY 2027	FY 2028
	(10 Mo.)		
FEDERAL FUNDS			
Income - DSS, MHD (§ 208.176)			
Reimbursement to FFS Pharmacy	\$386,233 to	\$411,338 to	\$438,075 to
Program for refill costs p. 3	\$4,590,474	\$4,888,855	\$5,206,631
<u>Costs</u> – DSS, MHD (§ 208.176) FFS	(\$386,233 to	(\$411,338 to	(\$438,075 to
Pharmacy Program refill costs p. 3	\$4,590,474)	<u>\$4,888,855)</u>	\$5,206,631)
ESTIMATED NET EFFECT ON			
FEDERAL FUNDS	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>

FISCAL IMPACT – Local Government	FY 2026	FY 2027	FY 2028
	(10 Mo.)		
	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>

### FISCAL IMPACT - Small Business

No direct fiscal impact to small businesses would be expected as a result of this proposal.

### FISCAL DESCRIPTION

This bill specifies that for MO HealthNet and for insurance carriers or health benefit plans, any prior authorization requirements for opioid analgesic and any service denials made thereto do not require the use of opioid analgesic drug products without abuse-deterrent properties before authorizing the use of such drug products.

The bill also requires insurance carriers or health benefits plans to provide coverage on their formulary or drug list at least one abuse-deterrent opioid analgesic drug product per opioid analgesics active ingredient.

Cost-sharing for brand name or generic versions of this product are not to exceed the lowest costsharing level applied to brand name or generic non-abuse deterrent opioid drugs covered under the applicable health plan or policy. Additionally, an increase in patient cost-sharing or disincentives for prescribers or dispensers is not allowed in order to achieve compliance with the provisions of this bill. (§ 208.176 and § 376.1239) L.R. No. 2277H.011 Bill No. HB 1118 Page **6** of **6** February 21, 2025

This legislation is not federally mandated, would not duplicate any other program and would not require additional capital improvements or rental space.

#### SOURCES OF INFORMATION

Department of Commerce and Insurance Department of Health and Senior Services Department of Public Safety – Missouri Highway Patrol Missouri Veterans Commission Department of Social Services Missouri Consolidated Health Care Plan Missouri Department of Conservation Missouri Department of Transportation Oversight Division

nere mouff

Julie Morff Director February 21, 2025

Jessica Harris Assistant Director February 21, 2025